| 摘要 |
<p>ABSTRACT - 601920 The disclosure relates to a crystalline form of compound 4-{ (1S, 2S)-2-[(4-cyclobutylpiperazin-1-yl)carbonyl]-cyclopropyl} -benzamide, represented by formula (I), pharmaceutical formulations containing said compound and to the use of said active compound in therapy. Said crystalline form is suitable for use in the treatment of a disorder selected from schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, neuropathic pain, Alzheimer’s disease, cognition deficiency, and cognition deficiency associated with schizophrenia.</p> |
